Wirtz S, Neurath M F
Laboratory of Immunology, I. Medical Clinic, University of Mainz, Germany.
Gene Ther. 2003 May;10(10):854-60. doi: 10.1038/sj.gt.3302013.
The pathogenesis of Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease, involves a complex interplay between certain genetic, environmental and immunological factors. Considerable research progress in the last decade defined key inflammatory pathways in the inflamed gut and identified new potential therapeutic targets. Since the current medical treatment with corticosteroids and anti-inflammatory drugs is often associated with undesired side effects and cannot completely cure IBD, these current advances in our understanding of intestinal pathology may now allow the development of new biologic treatment strategies including gene therapy. In this review, we will give a brief overview of potential gene therapy target molecules related to chronic intestinal inflammation. Furthermore, we summarize the results of recent preclinical studies for intestinal gene transfer and discuss future perspectives.
克罗恩病和溃疡性结肠炎是炎症性肠病的两种主要形式，其发病机制涉及某些遗传、环境和免疫因素之间的复杂相互作用。过去十年中取得的重大研究进展明确了炎症肠道中的关键炎症通路，并确定了新的潜在治疗靶点。由于目前使用皮质类固醇和抗炎药物进行的药物治疗常常伴有不良副作用，且无法完全治愈炎症性肠病，因此我们目前对肠道病理学的这些新认识或许能够催生包括基因治疗在内的新型生物治疗策略。在这篇综述中，我们将简要概述与慢性肠道炎症相关的潜在基因治疗靶点分子。此外，我们总结了近期肠道基因转移临床前研究的结果，并探讨未来前景。
